Urologic An issue of Salvage therapies for Non-Muscle Invasive Bladder Cancer, 1st Edition

Author :
Badrinath Konety
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the fol ...view more
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics:  BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure”; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy.  Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.
Add to Cart
Together with Consulting Editor Dr. Samir Taneja, Dr. Badrinath Konety has put together a comprehensive issue that addresses Salvage therapies for Non-Muscle Invasive Bladder Cancer. Expert authors have contributed clinical review articles on the following topics:  BCG salvage therapy: Definition and context; Who will respond to BCG? Predictors and nomograms; Identification of candidates for salvage therapy: Definition of BCG “Failure”; Predictors of response to Intravesical therapy; Precision medicine for NMIBC; Salvage therapy using BCG derivatives or single agent chemotherapy; Intravesical heated Mitomycin: Biology and clinical utility; Mitomycin derivatives in the salvage setting; Combination intravesical therapy; Intravesical gene therapy; Immunoncology as salvage therapy; Role of IDO inhibitors in salvage therapy; and Novel agents for intravesical therapy.  Readers will come away with the clinical information they need to improve outcomes in patients with bladder cancer.

Author Information
By Badrinath Konety